dihexa clinical trials humans First-In-Human Trial Requirement -BioPharma Services dihexa clinical trials human status

Many wound healing agents target just one mechanism, but BPC-157 appears to coordinate several processes simultaneously

It primarily works by promoting the formation of new blood vessels, a process vital for repairing damaged connective tissue

Research shows BPC-157 treatment accelerates healing of transected tendons through promotion of tendon outgrowth, cell survival, and cell migration via regulation of ERK1/2 phosphorylation and downstream targets including c-Fos, c-Jun, and Egr-1key molecules involved in cell growth, migration, and angiogenesis

A decentralized clinical trial is one that takes place fully remotely